Skip to contents

Clemens R. Scherzer, MD
Associate Neurologist, Brigham and Women's Hospital
Professor of Neurology, Harvard Medical School

Brigham and Women's Hospital
Department of Neurology
75 Francis Street
Boston, MA 02115


Edit Profile


Research Narrative:

Clemens R. Scherzer, MD directs The Neurogenomics Laboratory at Harvard Medical School and Brigham and Women’s Hospital, is the Co-Founder and Co-Director of the Harvard NeuroDiscovery Center Biomarkers Program, and Associate Professor of Neurology at Harvard Medical School.

The goal of the Scherzer Laboratory is to catalog and decipher all functional elements of the human genome in the human brain, and to determine how the normal flow of genetic information is corrupted in Parkinson’s, Huntington’s, and other neurodegenerative diseases. As physician-scientist Scherzer envisions and is building a future personalized Parkinson’s health care, where DNA, RNA, and biome barcodes are used for much earlier diagnosis, personalized prognosis, tailored treatments, and response tracking.

Dr. Scherzer is the recipient of the Dr. Paul Beeson Award, the George C. Cotzias Memorial Award, and an Edmond J. Safra Global Genetics Consortium Award of the Michael J. Fox Foundation. He serves on the Editorial Boards of Neurogenetics and Biomarkers in Medicine, and on the Steering Committees of the MJFF’s Parkinson Progression Marker Initiative (PPMI) as well as the NINDS’ Parkinson Biomarker Program (PDBP).

 


Education:
MD

Publications (Pulled from Harvard Catalyst Profiles):

1. O'Bryant SE, Edwards M, Zhang F, Johnson LA, Hall J, Kuras Y, Scherzer CR. Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study. Alzheimers Dement (Amst). 2019 Dec; 11:374-382.

2. Henderson-Smith A, Fisch KM, Hua J, Liu G, Ricciardelli E, Jepsen K, Huentelman M, Stalberg G, Edland SD, Scherzer CR, Dunckley T, Desplats P. DNA methylation changes associated with Parkinson's disease progression: outcomes from the first longitudinal genome-wide methylation analysis in blood. Epigenetics. 2019 Apr; 14(4):365-382.

3. Dong X, Liao Z, Gritsch D, Hadzhiev Y, Bai Y, Locascio JJ, Guennewig B, Liu G, Blauwendraat C, Wang T, Adler CH, Hedreen JC, Faull RLM, Frosch MP, Nelson PT, Rizzu P, Cooper AA, Heutink P, Beach TG, Mattick JS, Müller F, Scherzer CR. Publisher Correction: Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease. Nat Neurosci. 2019 Jan; 22(1):144-147.

4. Dong X, Liao Z, Gritsch D, Hadzhiev Y, Bai Y, Locascio JJ, Guennewig B, Liu G, Blauwendraat C, Wang T, Adler CH, Hedreen JC, Faull RLM, Frosch MP, Nelson PT, Rizzu P, Cooper AA, Heutink P, Beach TG, Mattick JS, Müller F, Scherzer CR. Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease. Nat Neurosci. 2018 10; 21(10):1482-1492.

5. Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, Buko A, Cedarbaum J, Chelsky D, Cookson MR, Dawson TM, Dewey R, Foroud T, Frasier M, German D, Gwinn K, Huang X, Kopil C, Kremer T, Lasch S, Marek K, Marto JA, Merchant K, Mollenhauer B, Naito A, Potashkin J, Reimer A, Rosenthal LS, Saunders-Pullman R, Scherzer CR, Sherer T, Singleton A, Sutherland M, Thiele I, van der Brug M, Van Keuren-Jensen K, Vaillancourt D, Walt D, West A, Zhang J. Finding useful biomarkers for Parkinson's disease. Sci Transl Med. 2018 Aug 15; 10(454).

6. Olsen AL, Riise T, Scherzer CR. Discovering New Benefits From Old Drugs With Big Data-Promise for Parkinson Disease. JAMA Neurol. 2018 Aug 01; 75(8):917-920.

7. Mittal S, Bjørnevik K, Im DS, Flierl A, Dong X, Locascio JJ, Abo KM, Long E, Jin M, Xu B, Xiang YK, Rochet JC, Engeland A, Rizzu P, Heutink P, Bartels T, Selkoe DJ, Caldarone BJ, Glicksman MA, Khurana V, Schüle B, Park DS, Riise T, Scherzer CR. ß2-Adrenoreceptor is a regulator of the a-synuclein gene driving risk of Parkinson's disease. Science. 2017 09 01; 357(6354):891-898.

8. Gwinn K, David KK, Swanson-Fischer C, Albin R, Hillaire-Clarke CS, Sieber BA, Lungu C, Bowman FD, Alcalay RN, Babcock D, Dawson TM, Dewey RB, Foroud T, German D, Huang X, Petyuk V, Potashkin JA, Saunders-Pullman R, Sutherland M, Walt DR, West AB, Zhang J, Chen-Plotkin A, Scherzer CR, Vaillancourt DE, Rosenthal LS. Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program. Biomark Med. 2017 May; 11(6):451-473.

9. Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR. Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. Lancet Neurol. 2017 08; 16(8):620-629.

10. Manocha GD, Floden AM, Puig KL, Nagamoto-Combs K, Scherzer CR, Combs CK. Defining the contribution of neuroinflammation to Parkinson's disease in humanized immune system mice. Mol Neurodegener. 2017 02 14; 12(1):17.